세계의 암 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Oncology Drugs Market is presumed to reach the market size of nearly USD 351.1 Billion by 2032 from USD 178.44 Billion in 2023 with a CAGR of 7.81% under the study period 2024-2032.

Oncology drugs refer to medications used for cancer treatment. A drug used in cancer treatment varies in structure and mechanism of action. It kills cancer cells, stops them from growing and spreading to other parts of the body, helps the body regain strength, and develop new healthy cells. It also treats symptoms that cancer causes, like pain. With advances in understanding cancer biology, better treatment options, including drugs, are being devised, leading to new products approval and launch.

MARKET DYNAMICS

The growing burden of cancer diseases drives the growth of the global oncology drugs market. According to the World Health Organization estimates, the worldwide cancer burden is assessed to have ascended to 18.1 million new cases, and 9.6 million passings in 2018. It is projected that by 2030 between 10 and 11 million cancers will be diagnosed each year in low- and middle-income countries. The expanding disease burden is because of a few elements, including the aging population, changing lifestyle, among others. The growing approval for new drugs by the FDA and rising penetration of health insurance is amplifying revenue growth. Malignant of the lung, female breast, and colorectum are the top three cancers in terms of incidence, estimated to hold the majority share in global terms. However, expensive treatment and limited treatment options restrain the growth of the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Oncology Drugs. The growth and trends of Oncology Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Oncology Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Modals

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Others

By Cancer Type

• Breast Cancer
• Blood Cancer
• Prostate Cancer
• Skin Cancer
• Lung Cancer
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Oncology Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Oncology Drugs market include Johnson & Johnson, Amgen Inc., Eli Lilly & Co., GlaxoSmithKline, Roche Diagnostics, Merck & Co., Pfizer, Sanofi, Celgene Corporation, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ONCOLOGY DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Modals
  • 3.7.2 Market Attractiveness Analysis By Cancer Type
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ONCOLOGY DRUGS MARKET ANALYSIS BY THERAPEUTIC MODALS

• 5.1. Overview By Therapeutic Modals
• 5.2. Historical and Forecast Data Analysis By Therapeutic Modals
• 5.3. Chemotherapy Historic and Forecast Sales By Regions
• 5.4. Targeted Therapy Historic and Forecast Sales By Regions
• 5.5. Immunotherapy Historic and Forecast Sales By Regions
• 5.6. Hormonal Therapy Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ONCOLOGY DRUGS MARKET ANALYSIS BY CANCER TYPE

• 6.1. Overview By Cancer Type
• 6.2. Historical and Forecast Data Analysis By Cancer Type
• 6.3. Breast Cancer Historic and Forecast Sales By Regions
• 6.4. Blood Cancer Historic and Forecast Sales By Regions
• 6.5. Prostate Cancer Historic and Forecast Sales By Regions
• 6.6. Skin Cancer Historic and Forecast Sales By Regions
• 6.7. Lung Cancer Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL ONCOLOGY DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE ONCOLOGY DRUGS COMPANIES

• 8.1. Oncology Drugs Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF ONCOLOGY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Johnson & Johnson
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Amgen Inc.
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Eli Lilly & Co.
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. GlaxoSmithKline
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Roche Diagnostics
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Merck & Co.
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Pfizer
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Sanofi
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Celgene Corporation
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Novartis AG
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies